Syncom Formulations (India) Limited
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and su… Read more
Syncom Formulations (India) Limited (SYNCOMF) - Total Assets
Latest total assets as of September 2025: ₹4.56 Billion INR
Based on the latest financial reports, Syncom Formulations (India) Limited (SYNCOMF) holds total assets worth ₹4.56 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Syncom Formulations (India) Limited - Total Assets Trend (2006–2025)
This chart illustrates how Syncom Formulations (India) Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Syncom Formulations (India) Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Syncom Formulations (India) Limited's total assets of ₹4.56 Billion consist of 65.3% current assets and 34.7% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 0.2% |
| Accounts Receivable | ₹1.29 Billion | 31.1% |
| Inventory | ₹413.32 Million | 10.0% |
| Property, Plant & Equipment | ₹0.00 | 0.0% |
| Intangible Assets | ₹472.00K | 0.0% |
| Goodwill | ₹0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Syncom Formulations (India) Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Syncom Formulations (India) Limited's current assets represent 65.3% of total assets in 2025, an increase from 53.4% in 2006.
- Cash Position: Cash and equivalents constituted 0.2% of total assets in 2025, down from 0.4% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 31.1% of total assets.
Syncom Formulations (India) Limited Competitors by Total Assets
Key competitors of Syncom Formulations (India) Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Syncom Formulations (India) Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Syncom Formulations (India) Limited generates 1.13x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Syncom Formulations (India) Limited generates $ 11.96 in net profit.
Syncom Formulations (India) Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.68 | 5.01 | 2.07 |
| Quick Ratio | 4.24 | 4.09 | 1.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₹2.39 Billion | ₹ 1.97 Billion | ₹ 601.61 Million |
Syncom Formulations (India) Limited - Advanced Valuation Insights
This section examines the relationship between Syncom Formulations (India) Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.26 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 2.1% |
| Total Assets | ₹4.13 Billion |
| Market Capitalization | $60.50 Million USD |
Valuation Analysis
Below Book Valuation: The market values Syncom Formulations (India) Limited's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Syncom Formulations (India) Limited's assets grew by 2.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Syncom Formulations (India) Limited (2006–2025)
The table below shows the annual total assets of Syncom Formulations (India) Limited from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹4.13 Billion | +2.13% |
| 2024-03-31 | ₹4.05 Billion | +7.10% |
| 2023-03-31 | ₹3.78 Billion | +22.58% |
| 2022-03-31 | ₹3.08 Billion | +5.69% |
| 2021-03-31 | ₹2.92 Billion | +61.56% |
| 2020-03-31 | ₹1.81 Billion | +4.37% |
| 2019-03-31 | ₹1.73 Billion | +1.17% |
| 2018-03-31 | ₹1.71 Billion | -5.11% |
| 2017-03-31 | ₹1.80 Billion | +2.72% |
| 2016-03-31 | ₹1.75 Billion | +27.47% |
| 2015-03-31 | ₹1.38 Billion | -1.74% |
| 2014-03-31 | ₹1.40 Billion | +13.97% |
| 2013-03-31 | ₹1.23 Billion | +8.99% |
| 2012-03-31 | ₹1.13 Billion | -0.29% |
| 2011-03-31 | ₹1.13 Billion | +22.47% |
| 2010-03-31 | ₹923.19 Million | +45.83% |
| 2009-03-31 | ₹633.06 Million | -6.88% |
| 2008-03-31 | ₹679.82 Million | +26.04% |
| 2007-03-31 | ₹539.38 Million | +14.02% |
| 2006-03-31 | ₹473.07 Million | -- |